Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade B 20.57 2.85% 0.57
CHRS closed up 2.85 percent on Wednesday, September 18, 2019, on 86 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CHRS trend table...

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Multiple of Ten Bullish Other -0.77%
Multiple of Ten Bullish Other 1.83%
NR7 Range Contraction 3.16%
Multiple of Ten Bearish Other 3.16%
Multiple of Ten Bullish Other 1.33%
Crossed Above 50 DMA Bullish 3.16%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.16%
Pocket Pivot Bullish Swing Setup 3.16%
Multiple of Ten Bearish Other 3.16%

Older signals for CHRS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biotechnology Biopharmaceutical Immunology Chemotherapy Breast Cancer Psoriasis Rheumatoid Arthritis Immunosuppressants Biosimilar Recombinant Proteins Treatment Of Breast Cancer Etanercept
Is CHRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.43
52 Week Low 8.32
Average Volume 824,756
200-Day Moving Average 16.0562
50-Day Moving Average 19.5456
20-Day Moving Average 21.1415
10-Day Moving Average 20.289
Average True Range 0.9919
ADX 15.13
+DI 19.8308
-DI 21.1024
Chandelier Exit (Long, 3 ATRs ) 19.8143
Chandelier Exit (Short, 3 ATRs ) 21.6357
Upper Bollinger Band 22.9509
Lower Bollinger Band 19.3321
Percent B (%b) 0.34
BandWidth 17.117045
MACD Line 0.0925
MACD Signal Line 0.2635
MACD Histogram -0.1709
Fundamentals Value
Market Cap 1.06 Billion
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -7.91
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.12
Resistance 3 (R3) 22.03 21.44 21.86
Resistance 2 (R2) 21.44 21.04 21.48 21.77
Resistance 1 (R1) 21.00 20.80 21.22 21.09 21.69
Pivot Point 20.41 20.41 20.52 20.45 20.41
Support 1 (S1) 19.97 20.01 20.19 20.06 19.45
Support 2 (S2) 19.38 19.77 19.42 19.37
Support 3 (S3) 18.94 19.38 19.28
Support 4 (S4) 19.03